The Application of Biomarkers in the Care of Patients With Atrial Fibrillation

NCT07565337 | Active Not Recruiting

• 1 other identifier: 202506174RINC
• Study Type: observational
• Target: 266
• Locations: 1 country
• Sites: 1

Brief Summary

From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Building on these findings, the present study aims to further validate these biomarkers in a larger subset of patients (n=266) who completed paired pre- and post-intervention sampling. Targeted biomarkers may include NT-proBNP, IL-6, hs-CRP, Adipsin, GDF-15, sST-2, FABP3, and IGF-BP3. Our goal is to identify markers associated with AF burden, assess their predictive performance and subgroup consistency, and further elucidate the underlying pathophysiological mechanisms.

Conditions

Atrial Fibrillation; Biomarker

Keywords

biomarker; atrial fibrillation; AF burden; inflammation; fibrosis; heart failure

Outcome Measures

Primary Outcomes (1)

• Novel biomarkers

  Whether novel biomarkers are associated with atrial fibrillation burden and could serve as tools to assist clinicians in diagnosing and treating patients, including tracking treatment effectiveness or the timeline for progression to heart failure;

  1YEARS

Study Arms (1)

afib

From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Building on these findings, the present study aims to further validate these biomarkers in a larger subset of patients (n=266) who completed paired pre- and post-intervention sampling. Targeted biomarkers may include NT-proBNP, IL-6, hs-CRP, Adipsin, GDF-15, sST-2, FABP3, and IGF-BP3. Our goal is to identify markers associated with AF burden, assess their predictive performance and subgroup consistency, and further elucidate the underlying pathophysiological mechanisms.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study is a follow-up to the prospective generational study (AFTTER: Atrial Fibrillation Trial To Eliminate Risk-factors; NCT05718336) that enrolled patients from 2020 to 2023. After consenting to participate in this study, patients underwent a series of questionnaires, blood tests, and special examinations (see the figure below). The caregiver (the arrhythmia treatment team at National Taiwan University Hospital) formulated a treatment plan based on the examination results. After approximately two years (at least one year) of treatment, a post-test was conducted to conclude the study (a total of 343 patients were enrolled in this study, of which 266 participants completed the pre- and post-treatment tests and blood tests).

You may qualify if:

• Who have signed up for the Protocol No. 202003090RINA(National Taiwan University Hospital Atrial Fibrillation Integrated Care Pilot Program)

You may not qualify if:

• Subjects without complete pre- and post-treatment testing

Sponsors & Collaborators

• National Taiwan University Hospital: lead

Study Sites (1)

National Taiwan University Hospita

Taipei, 100, Taiwan

Location

Biospecimen

Retention: SAMPLES WITH DNA

serum

MeSH Terms

Conditions

Atrial Fibrillation; Inflammation; Fibrosis; Heart Failure

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 7, 2026
• First Posted: May 4, 2026
• Study Start: January 1, 2026
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2028
• Last Updated: May 4, 2026

Record last verified: 2026-04

Locations

TW (1)